Amarin Corp Plc (AMRN)

[ziploc_1]

Rose....This is a critical time period for Vascepa.

If Europe (and possibly) China become profitable and Amarin can at least continue to break even in the U.S., Amarin can afford to wait until a once daily statin-EPA combo is available to market in the U.S. and the 'skinny label problem' at that time becomes an irrelevance.

Then Vascepa can resume its destiny to become a blockbuster drug, which was interrupted by the ninth circuit 'skinny label' decision.